Skip to main content
. 2012 Apr 3;54(10):1504–1513. doi: 10.1093/cid/cis225

Figure 2.

Figure 2.

Multiway sensitivity analyses: incremental cost-effectiveness of pre-exposure prophylaxis (PrEP). This figure reports the ranges of incremental cost-effectiveness ratios for PrEP as a function of the 3 most influential parameters identified in Figure 1: human immunodeficiency virus (HIV) infection incidence of 1%–11% annually (vertical axis), PrEP efficacy of 0%–95% (horizontal axis), and PrEP program cost (the 3 vertical panels). The color indicates the incremental cost-effectiveness ratio achieved by each combination of parameters, ranging from not cost-effective in red (ratio >$21 600 per year of life saved [YLS]), to cost-effective in yellow ($7200–21,600/YLS), to very cost-effective in orange (<$7200/YLS), to cost saving in green. A, Base PrEP program costs. B, Base PrEP program costs with 50% reduction in PrEP drug cost (from $55/year to $28/year). C, 50% reduction in base PrEP program costs (from $188/year to $94/year). The base case and CAPRISA 004, iPrEX, TDF2 and Partners PrEP trial point estimates are indicated in each panel by the (+).